AKN Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product

Akorn, Inc. (AMEX: AKN) today announced that it has signed an Exclusive Supply Agreement with PrimaPharm, Inc., a privately-held pharmaceutical company located in San Diego, California to supply Hydase, a branded, NDA drug product indicated as an adjuvant to increase the absorption and dispersion of other injected drugs. The total United States market size for Hyaluronidase Injection is $8.6M, according to 2006 IMS data. Hydase� will be manufactured by PrimaPharm, Inc., who owns the NDA. Hydase� formulation is preservative free and does not contain thimerosal, a mercury containing agent. Akorn will have exclusive marketing and distribution rights in the U.S. and Puerto Rico, and expects to launch the product in the first half of 2007. Arthur S. Przybyl, Akorn�s President and Chief Executive Officer stated, �This is a niche, NDA product that fits our marketing strategy in both our hospital and ophthalmic business segments. The fact that Hydase� does not contain thimerosal is an important competitive advantage over other marketed hyaluronidase drugs.� Zak Hassanein, President and CEO, PrimaPharm, Inc., stated �We are excited about Akorn�s marketing strength and their ability to position Hydase� in the surgical marketplace. Our partnership with Akorn will take advantage of the additional capacity available at our new, 50,000 square foot, state-of-the-art cGMP manufacturing facility in San Diego, due to open in early 2007.� About Akorn, Inc. Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals. Additional information is available at the Company�s website at www.akorn.com. About PrimaPharm Inc. PrimaPharm is a privately held developer and contract manufacturer of Drugs, Medical Devices and Diagnostics. Located in San Diego, California, the Company, in business since 1992, is a FDA inspected, cGMP manufacturer of high quality, Pharmaceutical and Medical Device products including aseptic injectables, liquids, gels, lyophilized drugs, ointments, creams, emulsions and suspensions with separate facilities for the manufacture of cytotoxic drugs. Additional information is available at the Company�s website at www.primapharm.net Materials in this press release may contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements give our expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future steps we may take, prospective products, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our actual results may vary materially, and there are not guarantees about the performance of our stock. Any forward-looking statements represent our expectations or forecasts only as of the date they were made and should not be relied upon as representing our expectations or forecasts as of any subsequent date. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise, even if our expectations or forecasts change. You are advised, however, to consult any further disclosures we make on related subjects in our reports filed with the SEC. In particular, you should read the discussion in the section entitled "Cautionary Statement Regarding Forward-Looking Statements" in our most recent Annual Report on Form 10-K, as it may be updated in subsequent reports filed with the SEC. That discussion covers certain risks, uncertainties and possibly inaccurate assumptions that could cause our actual results to differ materially from expected and historical results. Other factors besides those listed there could also adversely affect our results.